XEME Biopharma Holdings Inc.
OperatingBiotech · Irvine, CA
Financials
FY2018–FY2020 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Dec 22, 2021| Class | Outstanding | Votes / share | Share of total | Votes | Last price |
|---|---|---|---|---|---|
| Class A Common Stock | 914,591,800 | 1 | 95.8% | 69.6% | — |
| Class B Common Stock | 40,000,000 | 10 | 4.19% | 30.4% | — |
| Total | 954,591,800 | 100% | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- R2T Biopharma Inc.848M (88.8%) Jan 2021 → 40M (4.19%) Sep 2021
Principal holders% as the filing states it, Dec 22, 2021
- R2T Biopharma Inc.40,000,000 Class B Common Stock100.0%of Class B
- R2T Biopharma Inc.847,770,374 Class A Common Stock92.7%of Class A
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
SEC filings
View all 16 filings on EDGAR- Form 1-A POSDec 22, 20210001753926-21-000819EDGAR
- Form 1-SADec 22, 20210001753926-21-000817EDGAR
- Form 1-A POSSep 30, 20210001753926-21-000509EDGAR
- Form 1-KMay 3, 20210001753926-21-000121EDGAR
- Form 1-A POSJan 20, 20210001775196-21-000003EDGAR
- Form 1-A POSDec 22, 20200001775196-20-000013EDGAR
- Form 1-UAug 7, 20200001775196-20-000008EDGAR
- Form 1-SAJul 14, 20200001775196-20-000006EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.